Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02794857 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Neuraltus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
- 20
- Study locations
NCT02794857: Completed Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Neuraltus Pharmaceuticals.
NCT02794857 is a Phase 2 study of Amyotrophic Lateral Sclerosis that has completed, run by Neuraltus Pharmaceuticals. The registered enrollment target is 138 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02794857, a Phase 2 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Neuraltus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation. Half of participants will receive NP001 and the other half will receive placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NP001
Study Locations (20)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California, Irvine, Department of Neurology - Orange
- Forbes Norris MDA/ALS Research Center, CPMC - San Francisco
Arizona
- St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics - Phoenix
- Mayo Clinic Arizona - Scottsdale
Florida
- Mayo Clinic Florida - Jacksonville
- University of Miami Miller School of Medicine - Miami
North Carolina
- Carolinas Medical Center, Neurosciences Instutite-Neurology - Charlotte
- Duke Neurological Disorders Clinic at Morreene Road - Durham
Ohio
- Cleveland Clinic Foundation-Cleveland Clinic Hospital - Cleveland
- The Ohio State University Wexner Medical Center - Columbus
Georgia
- Emory University, Department of Neurology - Atlanta
Kansas
- University of Kansas Medical Center - Kansas City
Kentucky
- University of Kentucky, Albert B. Chandler Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2016-08-29 |
| Est. Completion | 2017-12-12 |
| Phase | Phase 2 |
What the finished NCT02794857 record still lists
NCT02794857 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02794857 names 20 study sites across 14 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT02794857 about?
NCT02794857 is a clinical study titled "Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation". This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation. Half of participants will receive NP001 and the other half will receive placebo.
What is the current status of trial NCT02794857?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2016-08-29. Estimated completion is 2017-12-12.
What conditions does trial NCT02794857 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT02794857?
The interventions under investigation include: Placebo (DRUG), NP001 (DRUG).
Who is sponsoring clinical trial NCT02794857?
This trial is sponsored by Neuraltus Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02794857 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02794857's enrollment target sits among peer trials
138 36th of 102 higher than 67 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI